151 related articles for article (PubMed ID: 20182872)
1. Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice.
Tang XD; Liang GP; Li C; Wan Y; Chen T; Chen L; Yu ST; Xiong Z; Fang DC; Wang GZ; Yang SM
Cancer Immunol Immunother; 2010 Jul; 59(7):1041-7. PubMed ID: 20182872
[TBL] [Abstract][Full Text] [Related]
2. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.
Chen T; Tang XD; Wan Y; Chen L; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
Neoplasia; 2008 Sep; 10(9):977-86. PubMed ID: 18714399
[TBL] [Abstract][Full Text] [Related]
3. Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors.
Wang GZ; Tang XD; Lü MH; Gao JH; Liang GP; Li N; Li CZ; Wu YY; Chen L; Cao YL; Fang DC; Yang SM
Cancer Prev Res (Phila); 2011 Aug; 4(8):1285-95. PubMed ID: 21505182
[TBL] [Abstract][Full Text] [Related]
4. Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo.
Tang XD; Wang GZ; Guo J; Lü MH; Li C; Li N; Chao YL; Li CZ; Wu YY; Hu CJ; Fang DC; Yang SM
Mol Cancer Ther; 2012 May; 11(5):1183-92. PubMed ID: 22442309
[TBL] [Abstract][Full Text] [Related]
5. In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies.
Tang XD; Guo SL; Wang GZ; Li N; Wu YY; Fang DC; Fan YH; Yang SM
Cancer Sci; 2014 Jan; 105(1):9-17. PubMed ID: 24152338
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells reconstituted with a human heparanase gene induce potent cytotoxic T-cell responses against gastric tumor cells in vitro.
Cai YG; Fang DC; Chen L; Tang XD; Chen T; Yu ST; Luo YH; Xiong Z; Wang DX; Yang SM
Tumour Biol; 2007; 28(4):238-46. PubMed ID: 17717429
[TBL] [Abstract][Full Text] [Related]
7. Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.
Zhang J; Yang J; Fan D; Tao H; Wang H; Yu T
Oncol Rep; 2013 May; 29(5):1955-61. PubMed ID: 23503586
[TBL] [Abstract][Full Text] [Related]
8. Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells.
Jia ZC; Tian Y; Huang ZM; Wang JX; Fu XL; Ni B; Wu YZ
Cancer Biol Ther; 2011 Feb; 11(4):395-400. PubMed ID: 21124073
[TBL] [Abstract][Full Text] [Related]
9. H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo.
Tang XD; Wan Y; Chen L; Chen T; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
Cancer Res; 2008 Mar; 68(5):1529-37. PubMed ID: 18316618
[TBL] [Abstract][Full Text] [Related]
10. Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes.
Dadaglio G; Morel S; Bauche C; Moukrim Z; Lemonnier FA; Van Den Eynde BJ; Ladant D; Leclerc C
Int Immunol; 2003 Dec; 15(12):1423-30. PubMed ID: 14645151
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).
Liao ZL; Tang XD; Lü MH; Wu YY; Cao YL; Fang DC; Yang SM; Guo H
Cancer Sci; 2012 Nov; 103(11):1920-8. PubMed ID: 22909416
[TBL] [Abstract][Full Text] [Related]
12. The immunogenicity of a novel cytotoxic T lymphocyte epitope from tumor antigen PL2L60 could be enhanced by 4-chlorophenylalanine substitution at position 1.
Shi RR; Liu J; Zou Z; Qi YM; Zhai MX; Zhai WJ; Gao YF
Cancer Immunol Immunother; 2013 Nov; 62(11):1723-32. PubMed ID: 24077852
[TBL] [Abstract][Full Text] [Related]
13. [Immune response of heparinase gene modified dendritic cell-based vaccine on gastric cancer cells].
Cai YG; Fang DC; Chen L; Wang DX; Luo YH; Tang XD; Chen T; Yang SM
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3122-7. PubMed ID: 17313764
[TBL] [Abstract][Full Text] [Related]
14. Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.
Alexander J; Oseroff C; Sidney J; Sette A
Hum Immunol; 2003 Feb; 64(2):211-23. PubMed ID: 12559623
[TBL] [Abstract][Full Text] [Related]
15. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
Ji J; Judkowski VA; Liu G; Wang H; Bunying A; Li Z; Xu M; Bender J; Pinilla C; Yu JS
Stem Cells Transl Med; 2014 Mar; 3(3):356-64. PubMed ID: 24375541
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
[TBL] [Abstract][Full Text] [Related]
18. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
Street MD; Doan T; Herd KA; Tindle RW
Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.
Han JF; Zhao TT; Liu HL; Lin ZH; Wang HM; Ruan ZH; Zou LY; Wu YZ
Cancer Immunol Immunother; 2006 Dec; 55(12):1575-83. PubMed ID: 16534571
[TBL] [Abstract][Full Text] [Related]
20. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.
Schmidt SM; Schag K; Müller MR; Weinschenk T; Appel S; Schoor O; Weck MM; Grünebach F; Kanz L; Stevanovic S; Rammensee HG; Brossart P
Cancer Res; 2004 Feb; 64(3):1164-70. PubMed ID: 14871853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]